Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents
Julio Rosenstock,Denise Franco,Vadym Korpachev,Brad Shumel,Yuhui Ma,Robert A. Baughman,Nikhil Amin,Janet B. McGill +7 more
TL;DR: Prandial TI added to one or more OADs in inadequately controlled T2D is an effective treatment option and postprandial hyperglycemia, based on 7-point glucose profiles, was effectively controlled by TI.
Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study
Lauren K. Park,Kian-Huat Lim,Jonas J. Volkman,Mina Abdiannia,Zack Nigogosyan,Marilyn J. Siegel,Janet B. McGill,Alexis McKee,Maamoun Salam,Rong M. Zhang,Da Ma,Karteek Popuri,Vincent Chow,Mirza Faisal Beg,William G. Hawkins,Linda R. Peterson,Joseph E. Ippolito +16 more
TL;DR: In this article , the safety and tolerability of dapagliflozin (5 mg p.o.o/day × 2 weeks escalated to 10 mgp.o./day × 6 weeks) added to standard Gemcitabine and nab-Paclitaxel (GnP) chemotherapy in patients with locally advanced and/or metastatic PDAC was evaluated.
D-chiro-inositol metabolism in diabetes mellitus
Richard E. Ostlund,Janet B. McGill,Ian Herskowitz,David M. Kipnis,Julio V. Santiago,William R. Sherman +5 more
TL;DR: The metabolism of D-chiro-inositol is abnormal in diabetes and appears to be influenced by short- and long-term metabolic control.
Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment:
Janet B. McGill,Anthony H. Barnett,Andrew J Lewin,Sanjay Patel,Dietmar Neubacher,Maximilian von Eynatten,Hans-Juergen Woerle +6 more
TL;DR: It is suggested that linagliptin is a safe and effective glucose-lowering treatment in T2DM patients with moderate-to-severe RI for whom sulphonylurea treatment is no longer sufficient.